Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic bone marrow mesenchymal stem cells for refractory perianal Crohn's fistulas
NL-OMON36386Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Feb 2011
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Randomised, open-label trial of allogeneic bone marrow-derived mesenchymal stromal cells in Crohn's disease and anal fistula (6 cohorts), sponsored by Leiden University Medical Center. Primary endpoints: Safety and tolerability and Fistula response efficacy. Started Feb 2011; status: active, not recruiting.
02
Drugs
allogeneic bone marrow-derived mesenchymal stromal cells
03
Conditions
Crohn's diseaseanal fistula
Beyond the preview
Go deeper on NL-OMON36386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36386.